A Randomized, Double-blind, Parallel-group, 52-week Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Latest Information Update: 24 Mar 2026
At a glance
- Drugs Itepekimab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- Acronyms CEREN-4
- Sponsors Sanofi
Most Recent Events
- 24 Mar 2026 New trial record